The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function

Renal Transplant Clinical Trial

Official title:

The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03107858
• Other study ID #: NorepivsDopamine
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: March 24, 2017
• Last updated: October 18, 2017
• Start date: November 1, 2017
• Est. completion date: November 1, 2019

Study information

• Verified date: October 2017
• Source: Assiut University
• Contact: Ahmed Elkadi, MBBC
• Phone: +201007485190
• Email: ahmedkader333[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Renal transplantation is now recognized as a treatment of choice for patients with chronic renal failure with end-stage renal disease. Renal transplantations are associated with better quality of life, better cost/benefit ratio, and possibly longer survival. Significant changes in blood pressure are common throughout the surgical procedure for kidney transplantation. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: November 1, 2019
• Est. primary completion date: January 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients scheduled for a living donor kidney transplantation

Exclusion Criteria:

• Patients (less than 18 years old)

• Patients' refusal of consenting for enrolment in the study

Related Conditions & MeSH terms

• Renal Transplant

Intervention

Drug:
• Norepinephrine
Norepinephrine infusion will be used at a starting dose of 0.05µg/kg/min. Dose range: 0.05 -0.15 µg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
• Dopamine
Dopamine infusion will be used at a starting dose of 5µg/kg/min. Dose range: 5 -15 µg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative

Locations

Country	Name	City	State
Egypt	Assiut University Hospital	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum creatinine	postoperative	four hours postoperatively
Secondary	blood urea	postoperative	four hours postoperatively
Secondary	urine output	postoperative	over 24 hours
Secondary	renal artery diameter	Measured postoperative through renal artery Doppler	four hours postoperatively
Secondary	renal artery blood flow	Measured postoperative through renal artery Doppler	four hours postoperatively